For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, "Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Mild To Moderate Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Mild To Moderate Plaque Psoriasis Understanding
Mild To Moderate Plaque Psoriasis: Overview
Psoriasis is a genetically determined, systemic, immune-mediated long-term inflammatory condition that affects the skin, nails and joints. When psoriasis affects more than 5 percent of your body, it's considered moderate to severe. It may affect your genitals, face, hands, and feet. Biologic drugs are a popular treatment option for this type of psoriasis. Biologics may be used alone or with other treatments to ease your psoriasis. The doctor may assess the severity by looking at the physical symptoms of psoriasis. They may look for erythema (redness), scaling, and induration (lesion thickness). These three signs are often used to classify the severity of psoriasis.
"Mild To Moderate Plaque Psoriasis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Mild To Moderate Plaque Psoriasis pipeline landscape is provided which includes the disease overview and Mild To Moderate Plaque Psoriasis treatment guidelines. The assessment part of the report embraces, in depth Mild To Moderate Plaque Psoriasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Mild To Moderate Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Mild To Moderate Plaque Psoriasis R&D. The therapies under development are focused on novel approaches to treat/improve Mild To Moderate Plaque Psoriasis.
Mild To Moderate Plaque Psoriasis Emerging Drugs Chapters
This segment of the Mild To Moderate Plaque Psoriasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Mild To Moderate Plaque Psoriasis Emerging Drugs
- Roflumilast topical: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis. The drug is currently in phase 3 of clinical trials for the treatment of mild to moderate psoriasis.
- CC-90006: AnaptysBio
AnaptysBio-generated anti-inflammatory antibody programs, and has initiated a Phase 1 trial for CC-90006, a PD-1 agonist antibody, which is indicated for psoriasis.
Further product details are provided in the report ..
Mild To Moderate Plaque Psoriasis: Therapeutic Assessment
This segment of the report provides insights about the different Mild To Moderate Plaque Psoriasis drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Mild To Moderate Plaque Psoriasis
There are approx. 4+ key companies which are developing the therapies for Mild To Moderate Plaque Psoriasis. The companies which have their Mild To Moderate Plaque Psoriasis drug candidates in the most advanced stage, i.e. phase III include, Acrutis Biotherapeutics Biopharma.
Phases
DelveInsight's report covers around 4+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Mild To Moderate Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Mild To Moderate Plaque Psoriasis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Mild To Moderate Plaque Psoriasis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Mild To Moderate Plaque Psoriasis drugs.
Mild To Moderate Plaque Psoriasis Report Insights
- Mild To Moderate Plaque Psoriasis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Mild To Moderate Plaque Psoriasis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Mild To Moderate Plaque Psoriasis drugs?
- How many Mild To Moderate Plaque Psoriasis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Mild To Moderate Plaque Psoriasis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Mild To Moderate Plaque Psoriasis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Mild To Moderate Plaque Psoriasis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Acrutis Biotherapeutics
- AnaptysBio
- Evelo Biosciences
Key Products
- Roflumilast topical
- CC-90006
- EDP1815